Cervical malignancy is known as one of the important cancers which is originated from cervix. This malignancy has been observed in women infected with papillomavirus who had regular oral contraceptives, multiple pregnancies, and sexual relations. Early and fast cervical cancer diagnosis is known as two important aspects of cervical cancer therapy. Several investigations indicated that early and fast detection of cervical cancer could be associated with better treatment process and increasing survival rate of patients with this malignancy. Imaging techniques are very important diagnosis tools that could be employed for diagnosis and following responses to therapy in various cervical cancer stages. Multiple lines of evidence indicated that utilization of imaging techniques is related to some limitations (i.e. high cost, and invasive effects). Hence, it seems that along with using imaging techniques, finding and developing new biomarkers could be useful in the diagnosis and treatment of subjects with cervical cancer. Taken together, many studies showed that a variety of biomarkers including, several proteins, mRNAs, microRNAs, exosomes and polymorphisms might be introduced as prognostic, diagnostic and therapeutic biomarkers in cervical cancer therapy. In this review article, we highlighted imaging techniques as well as novel biomarkers for the diagnosis of cervical cancer.

宫颈恶性肿瘤被称为起源于宫颈的重要癌症之一。这种恶性肿瘤已在感染乳头瘤病毒、定期口服避孕药、多胎妊娠和发生性关系的妇女中观察到。宫颈癌早期和快速诊断被称为宫颈癌治疗的两个重要方面。多项研究表明，宫颈癌的早期和快速检测可能与更好的治疗过程和提高该恶性肿瘤患者的生存率有关。成像技术是非常重要的诊断工具，可用于诊断和跟踪各种宫颈癌阶段的治疗反应。多条证据表明，成像技术的使用与一些限制有关（即高成本和侵入性效应）。因此，似乎除了使用成像技术外，寻找和开发新的生物标志物可能有助于宫颈癌患者的诊断和治疗。综上所述，许多研究表明，多种生物标志物，包括几种蛋白质、mRNA、microRNA、外泌体和多态性，可能会被引入宫颈癌治疗中作为预后、诊断和治疗的生物标志物。在这篇综述文章中，我们重点介绍了用于诊断宫颈癌的成像技术和新型生物标志物。外泌体和多态性可能被引入作为宫颈癌治疗的预后、诊断和治疗生物标志物。在这篇综述文章中，我们重点介绍了用于诊断宫颈癌的成像技术和新型生物标志物。外泌体和多态性可能被引入作为宫颈癌治疗的预后、诊断和治疗生物标志物。在这篇综述文章中，我们重点介绍了用于诊断宫颈癌的成像技术和新型生物标志物。